骨化二醇治疗与COVID-19相关结局
这是一项2020年3–5月在西班牙巴塞罗那进行的观察性队列研究,纳入930例COVID-19住院患者,排除92例既往骨化二醇使用者后分析838例。入院时接受骨化二醇治疗(第1天532 μg,第3、7、15、30天各266 μg)的447例患者,ICU入住率和死亡率均显著低于未治疗组。
要点
- 骨化二醇治疗组ICU入住率为4.5%,未治疗组为21%(P < .001)。
- 意向性分析中治疗组死亡率为4.7%,未治疗组为15.9%(P = .001)。
- 调整年龄、性别、基线25(OH)D水平和合并症后,骨化二醇与ICU入住风险降低相关(OR 0.13;95% CI 0.07-0.23)。
核心结论
- 在COVID-19住院患者中,骨化二醇治疗显著降低了ICU入住率和死亡率。
研究设计与样本
- 观察性队列研究,2020年3–5月在西班牙巴塞罗那Hospital del Mar的COVID-19病房进行。
- 共纳入930例COVID-19患者,排除92例既往骨化二醇使用者,分析838例。
- 447例入院时接受骨化二醇治疗(第1天532 μg,第3、7、15、30天各266 μg),391例未治疗(意向性分析)。
- 未治疗组中53例后续在ICU期间接受治疗,在二次分析中归入治疗组。
主要发现
- 102例(12.2%)需要ICU支持。
- 治疗组447例中20例(4.5%)需要ICU,未治疗组391例中82例(21%)需要ICU(P < .001)。
- 调整年龄、性别、基线线性化25-羟基维生素D水平和合并症后,治疗组需要ICU的风险降低(OR 0.13;95% CI 0.07-0.23)。
- 总体死亡率为10%。
- 意向性分析中,治疗组447例中21例(4.7%)死亡,未治疗组391例中62例(15.9%)死亡(P = .001)。
关键数值与推荐
- 骨化二醇给药方案:第1天532 μg,第3、7、15、30天各266 μg。
- 在健康个体中,骨化二醇按重量计的效力约为胆钙化醇的3.2倍。
临床怎么用
- 对于COVID-19住院患者,可考虑使用骨化二醇以降低ICU入住和死亡风险。
- 临床决策时应结合患者基线维生素D水平、年龄、合并症等因素综合评估。
局限性
- 本研究为观察性队列研究,可能存在残余混杂。
- 未治疗组中部分患者后续在ICU接受治疗,二次分析中归入治疗组可能引入偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: COVID-19 is a major health problem because of saturation of intensive care units (ICU) and mortality. Vitamin D has emerged as a potential treatment able to reduce the disease severity. OBJECTIVE: This work aims to elucidate the effect of 25(OH)D3 (calcifediol) treatment on COVID-19-related outcomes. METHODS: This observational cohort study was conducted from March to May 2020, among patients admitted to COVID-19 wards of Hospital del Mar, Barcelona, Spain. A total of 930 patients with COVID-19 were included; 92 were excluded because of previous calcifediol intake. Of the remaining 838, a total of 447 received calcifediol (532 μg on day 1 plus 266 μg on days 3, 7, 15, and 30), whereas 391 were not treated at the time of hospital admission (intention-to-treat). Of the latter, 53 patients were treated later during ICU admission and were allocated in the treated group in a second analysis. In healthy individuals, calcifediol is about 3.2-fold more potent on a weight basis than cholecalciferol. Main outcome measures were ICU admission and mortality. RESULTS: ICU assistance was required by 102 (12.2%) participants. Out of 447 patients treated with calcifediol at admission, 20 (4.5%) required the ICU, compared to 82 (21%) out of 391 nontreated (P < .001). Logistic regression of calcifediol treatment on ICU admission, adjusted by age, sex, linearized 25-hydroxyvitamin D levels at baseline, and comorbidities showed that treated patients had a reduced risk of requiring the ICU (odds ratio [OR] 0.13; 95% CI 0.07-0.23). Overall mortality was 10%. In the intention-to-treat analysis, 21 (4.7%) out of 447 patients treated with calcifediol at admission died compared to 62 patients (15.9%) out of 391 nontreated (P = .001). Adjusted results showed a reduced mortality risk with an OR of 0.21 (95% CI, 0.10-0.43). In the second analysis, the obtained OR was 0.52 (95% CI, 0.27-0.99). CONCLUSION: In patients hospitalized with COVID-19, calcifediol treatment significantly reduced ICU admission and mortality.
引用
- Nogues X, Ovejero D, Pineda-Moncusí M, et al. Calcifediol Treatment and COVID-19-Related Outcomes. J Clin Endocrinol Metab. 2021. PMID: 34097036. doi:10.1210/clinem/dgab405
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。